Evidence map›Paper›PMID 40600013›Full record

ReviewFrontiers in endocrinology2025

Application progress of artificial intelligence in managing thyroid disease.

Qing Lu, Yu Wu, Jing Chang, Li Zhang, Qing Lv, Hui Sun

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qing Lu *Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu Wu *Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jing ChangDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li ZhangDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qing LvDepartment of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hui SunDepartment of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) has been used to study thyroid diseases since the 1990s. Previously, it mainly concentrated on the diagnosis of thyroid function and distinguishing benign from malignant thyroid nodules. With the rapid development of machine and deep learning, AI has been widely used in multiple areas of thyroid disease management, including image analysis, pathological diagnosis, personalized treatment, patient monitoring, and follow-up. This review systematically examines the evolution of AI applications in thyroid disease management since the 1990s, with a focus on diagnostic innovations, therapeutic personalization, and emerging challenges in clinical implementation. AI not only reduces the subjectivity associated with ultrasound examinations but also enhances the differentiation rate of benign and malignant thyroid nodules, thereby reducing the frequency of unnecessary fine-needle aspirations. AI synthesizes multimodal data, such as ultrasound, electronic health records, and wearable sensors, for continuous health monitoring. This integration facilitates the early detection of subclinical recurrence risk, particularly in patients who have undergone thyroidectomy. Despite the broad prospects of AI applications, challenges related to data privacy, model interpretability, and clinical applicability remain. This review critically evaluates studies across the ultrasound, CT/MRI, and histopathology domains, while addressing barriers to clinical translation, such as data heterogeneity and ethical concerns.

Indexed as

Artificial IntelligenceThyroid DiseasesDisease ManagementHumansartificial intelligencedeep learningpathologyradiomicsthyroid noduleultrasonography

Identifiers

PMID40600013
PMCPMC12208828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.